Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | OTC | P00480 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25944862 | 0.80 | ALB (0.36) | ALB | |
| SCHEMBL26225750 | 0.80 | ALB (0.37) | ALB | |
| SCHEMBL26225768 | 0.80 | ALB (0.33) | ALBTSHR | |
| SCHEMBL24629997 | 0.78 | CASP2 (0.49) | — | |
| SCHEMBL26759938 | 0.78 | GLP1R (0.38) | ALBTSHR | |
| SCHEMBL15076070 | 0.77 | SLC6A5 (0.40) | TSHRALDH1A1 | |
| SCHEMBL29328700 | 0.76 | TSHR (0.35) | TSHR | |
| SCHEMBL24920307 | 0.76 | TSHR (0.35) | TSHR | |
| SCHEMBL25360834 | 0.76 | NOS3 (0.40) | OTCNOD1ALDH1A1 | |
| SCHEMBL25360824 | 0.76 | NOS3 (0.40) | OTCNOD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | MEDIKINE, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | MEDIKINE, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11718654-B2 | IL-2R-βγ binding compounds | MEDIKINE, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718654-B2 | IL-2R-βγ binding compounds | MEDIKINE, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331801-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS | IL2RA, IL2, IL15RA | ALB 1363/4885OTC 4616/4885DPP7 2427/4885 |
| US-11718654-B2 | IL-2R-βγ binding compounds | IL2RA, IL2, IL1RN | ALB 2282/4885OTC 4773/4885DPP7 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.